Global Sympathomimetic Agents Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 306855
  • calendar_today Published On: Jun, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Sympathomimetic Agents market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Sympathomimetic Agents market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Anaphylaxis accounting for % of the Sympathomimetic Agents global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Dobutamine segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Sympathomimetic Agents include Pfizer, Sanofi, Novartis, Sterimax, and Bedford Pharmaceuticals, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Sympathomimetic Agents market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Dobutamine

Dopamine

Ephedrine

Epinephrine

Isoproterenol

Mephentermine

Metaraminol

Methoxamine

Norepinephrine

Phenylephrine

Market segment by Application, can be divided into

Anaphylaxis

Cardiac Arrest

Others

Market segment by players, this report covers

Pfizer

Sanofi

Novartis

Sterimax

Bedford Pharmaceuticals

Teva

Amneal Biosciences

Baxter Laboratories

Hikma Pharmaceuticals

Amphastar Pharmaceuticals

Marathon Pharmaceuticals

Bausch Health Companies

Sterling-Winthrop

Cipla USA

Nexus Pharmaceuticals

Mylan

Impax

ALK Abello

Lincoln Medical

Amphastar

Emerade

Grand Pharma

Harvest Pharmaceuticals

Merit Pharmaceutical

Tianjin Jinyao Group

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Sympathomimetic Agents product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Sympathomimetic Agents, with revenue, gross margin and global market share of Sympathomimetic Agents from 2019 to 2022.

Chapter 3, the Sympathomimetic Agents competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Sympathomimetic Agents market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Sympathomimetic Agents research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Sympathomimetic Agents

1.2 Classification of Sympathomimetic Agents by Type

1.2.1 Overview: Global Sympathomimetic Agents Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Sympathomimetic Agents Revenue Market Share by Type in 2021

1.2.3 Dobutamine

1.2.4 Dopamine

1.2.5 Ephedrine

1.2.6 Epinephrine

1.2.7 Isoproterenol

1.2.8 Mephentermine

1.2.9 Metaraminol

1.2.10 Methoxamine

1.2.11 Norepinephrine

1.2.12 Phenylephrine

1.3 Global Sympathomimetic Agents Market by Application

1.3.1 Overview: Global Sympathomimetic Agents Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Anaphylaxis

1.3.3 Cardiac Arrest

1.3.4 Others

1.4 Global Sympathomimetic Agents Market Size & Forecast

1.5 Global Sympathomimetic Agents Market Size and Forecast by Region

1.5.1 Global Sympathomimetic Agents Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Sympathomimetic Agents Market Size by Region, (2017-2022)

1.5.3 North America Sympathomimetic Agents Market Size and Prospect (2017-2028)

1.5.4 Europe Sympathomimetic Agents Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Sympathomimetic Agents Market Size and Prospect (2017-2028)

1.5.6 South America Sympathomimetic Agents Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Sympathomimetic Agents Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Sympathomimetic Agents Market Drivers

1.6.2 Sympathomimetic Agents Market Restraints

1.6.3 Sympathomimetic Agents Trends Analysis

2 Company Profiles

2.1 Pfizer

2.1.1 Pfizer Details

2.1.2 Pfizer Major Business

2.1.3 Pfizer Sympathomimetic Agents Product and Solutions

2.1.4 Pfizer Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Pfizer Recent Developments and Future Plans

2.2 Sanofi

2.2.1 Sanofi Details

2.2.2 Sanofi Major Business

2.2.3 Sanofi Sympathomimetic Agents Product and Solutions

2.2.4 Sanofi Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Sanofi Recent Developments and Future Plans

2.3 Novartis

2.3.1 Novartis Details

2.3.2 Novartis Major Business

2.3.3 Novartis Sympathomimetic Agents Product and Solutions

2.3.4 Novartis Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Novartis Recent Developments and Future Plans

2.4 Sterimax

2.4.1 Sterimax Details

2.4.2 Sterimax Major Business

2.4.3 Sterimax Sympathomimetic Agents Product and Solutions

2.4.4 Sterimax Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Sterimax Recent Developments and Future Plans

2.5 Bedford Pharmaceuticals

2.5.1 Bedford Pharmaceuticals Details

2.5.2 Bedford Pharmaceuticals Major Business

2.5.3 Bedford Pharmaceuticals Sympathomimetic Agents Product and Solutions

2.5.4 Bedford Pharmaceuticals Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Bedford Pharmaceuticals Recent Developments and Future Plans

2.6 Teva

2.6.1 Teva Details

2.6.2 Teva Major Business

2.6.3 Teva Sympathomimetic Agents Product and Solutions

2.6.4 Teva Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Teva Recent Developments and Future Plans

2.7 Amneal Biosciences

2.7.1 Amneal Biosciences Details

2.7.2 Amneal Biosciences Major Business

2.7.3 Amneal Biosciences Sympathomimetic Agents Product and Solutions

2.7.4 Amneal Biosciences Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Amneal Biosciences Recent Developments and Future Plans

2.8 Baxter Laboratories

2.8.1 Baxter Laboratories Details

2.8.2 Baxter Laboratories Major Business

2.8.3 Baxter Laboratories Sympathomimetic Agents Product and Solutions

2.8.4 Baxter Laboratories Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Baxter Laboratories Recent Developments and Future Plans

2.9 Hikma Pharmaceuticals

2.9.1 Hikma Pharmaceuticals Details

2.9.2 Hikma Pharmaceuticals Major Business

2.9.3 Hikma Pharmaceuticals Sympathomimetic Agents Product and Solutions

2.9.4 Hikma Pharmaceuticals Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Hikma Pharmaceuticals Recent Developments and Future Plans

2.10 Amphastar Pharmaceuticals

2.10.1 Amphastar Pharmaceuticals Details

2.10.2 Amphastar Pharmaceuticals Major Business

2.10.3 Amphastar Pharmaceuticals Sympathomimetic Agents Product and Solutions

2.10.4 Amphastar Pharmaceuticals Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Amphastar Pharmaceuticals Recent Developments and Future Plans

2.11 Marathon Pharmaceuticals

2.11.1 Marathon Pharmaceuticals Details

2.11.2 Marathon Pharmaceuticals Major Business

2.11.3 Marathon Pharmaceuticals Sympathomimetic Agents Product and Solutions

2.11.4 Marathon Pharmaceuticals Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Marathon Pharmaceuticals Recent Developments and Future Plans

2.12 Bausch Health Companies

2.12.1 Bausch Health Companies Details

2.12.2 Bausch Health Companies Major Business

2.12.3 Bausch Health Companies Sympathomimetic Agents Product and Solutions

2.12.4 Bausch Health Companies Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Bausch Health Companies Recent Developments and Future Plans

2.13 Sterling-Winthrop

2.13.1 Sterling-Winthrop Details

2.13.2 Sterling-Winthrop Major Business

2.13.3 Sterling-Winthrop Sympathomimetic Agents Product and Solutions

2.13.4 Sterling-Winthrop Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Sterling-Winthrop Recent Developments and Future Plans

2.14 Cipla USA

2.14.1 Cipla USA Details

2.14.2 Cipla USA Major Business

2.14.3 Cipla USA Sympathomimetic Agents Product and Solutions

2.14.4 Cipla USA Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 Cipla USA Recent Developments and Future Plans

2.15 Nexus Pharmaceuticals

2.15.1 Nexus Pharmaceuticals Details

2.15.2 Nexus Pharmaceuticals Major Business

2.15.3 Nexus Pharmaceuticals Sympathomimetic Agents Product and Solutions

2.15.4 Nexus Pharmaceuticals Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15.5 Nexus Pharmaceuticals Recent Developments and Future Plans

2.16 Mylan

2.16.1 Mylan Details

2.16.2 Mylan Major Business

2.16.3 Mylan Sympathomimetic Agents Product and Solutions

2.16.4 Mylan Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.16.5 Mylan Recent Developments and Future Plans

2.17 Impax

2.17.1 Impax Details

2.17.2 Impax Major Business

2.17.3 Impax Sympathomimetic Agents Product and Solutions

2.17.4 Impax Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.17.5 Impax Recent Developments and Future Plans

2.18 ALK Abello

2.18.1 ALK Abello Details

2.18.2 ALK Abello Major Business

2.18.3 ALK Abello Sympathomimetic Agents Product and Solutions

2.18.4 ALK Abello Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.18.5 ALK Abello Recent Developments and Future Plans

2.19 Lincoln Medical

2.19.1 Lincoln Medical Details

2.19.2 Lincoln Medical Major Business

2.19.3 Lincoln Medical Sympathomimetic Agents Product and Solutions

2.19.4 Lincoln Medical Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.19.5 Lincoln Medical Recent Developments and Future Plans

2.20 Amphastar

2.20.1 Amphastar Details

2.20.2 Amphastar Major Business

2.20.3 Amphastar Sympathomimetic Agents Product and Solutions

2.20.4 Amphastar Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.20.5 Amphastar Recent Developments and Future Plans

2.21 Emerade

2.21.1 Emerade Details

2.21.2 Emerade Major Business

2.21.3 Emerade Sympathomimetic Agents Product and Solutions

2.21.4 Emerade Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.21.5 Emerade Recent Developments and Future Plans

2.22 Grand Pharma

2.22.1 Grand Pharma Details

2.22.2 Grand Pharma Major Business

2.22.3 Grand Pharma Sympathomimetic Agents Product and Solutions

2.22.4 Grand Pharma Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.22.5 Grand Pharma Recent Developments and Future Plans

2.23 Harvest Pharmaceuticals

2.23.1 Harvest Pharmaceuticals Details

2.23.2 Harvest Pharmaceuticals Major Business

2.23.3 Harvest Pharmaceuticals Sympathomimetic Agents Product and Solutions

2.23.4 Harvest Pharmaceuticals Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.23.5 Harvest Pharmaceuticals Recent Developments and Future Plans

2.24 Merit Pharmaceutical

2.24.1 Merit Pharmaceutical Details

2.24.2 Merit Pharmaceutical Major Business

2.24.3 Merit Pharmaceutical Sympathomimetic Agents Product and Solutions

2.24.4 Merit Pharmaceutical Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.24.5 Merit Pharmaceutical Recent Developments and Future Plans

2.25 Tianjin Jinyao Group

2.25.1 Tianjin Jinyao Group Details

2.25.2 Tianjin Jinyao Group Major Business

2.25.3 Tianjin Jinyao Group Sympathomimetic Agents Product and Solutions

2.25.4 Tianjin Jinyao Group Sympathomimetic Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.25.5 Tianjin Jinyao Group Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Sympathomimetic Agents Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Sympathomimetic Agents Players Market Share in 2021

3.2.2 Top 10 Sympathomimetic Agents Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Sympathomimetic Agents Players Head Office, Products and Services Provided

3.4 Sympathomimetic Agents Mergers & Acquisitions

3.5 Sympathomimetic Agents New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Sympathomimetic Agents Revenue and Market Share by Type (2017-2022)

4.2 Global Sympathomimetic Agents Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Sympathomimetic Agents Revenue Market Share by Application (2017-2022)

5.2 Global Sympathomimetic Agents Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Sympathomimetic Agents Revenue by Type (2017-2028)

6.2 North America Sympathomimetic Agents Revenue by Application (2017-2028)

6.3 North America Sympathomimetic Agents Market Size by Country

6.3.1 North America Sympathomimetic Agents Revenue by Country (2017-2028)

6.3.2 United States Sympathomimetic Agents Market Size and Forecast (2017-2028)

6.3.3 Canada Sympathomimetic Agents Market Size and Forecast (2017-2028)

6.3.4 Mexico Sympathomimetic Agents Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Sympathomimetic Agents Revenue by Type (2017-2028)

7.2 Europe Sympathomimetic Agents Revenue by Application (2017-2028)

7.3 Europe Sympathomimetic Agents Market Size by Country

7.3.1 Europe Sympathomimetic Agents Revenue by Country (2017-2028)

7.3.2 Germany Sympathomimetic Agents Market Size and Forecast (2017-2028)

7.3.3 France Sympathomimetic Agents Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Sympathomimetic Agents Market Size and Forecast (2017-2028)

7.3.5 Russia Sympathomimetic Agents Market Size and Forecast (2017-2028)

7.3.6 Italy Sympathomimetic Agents Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Sympathomimetic Agents Revenue by Type (2017-2028)

8.2 Asia-Pacific Sympathomimetic Agents Revenue by Application (2017-2028)

8.3 Asia-Pacific Sympathomimetic Agents Market Size by Region

8.3.1 Asia-Pacific Sympathomimetic Agents Revenue by Region (2017-2028)

8.3.2 China Sympathomimetic Agents Market Size and Forecast (2017-2028)

8.3.3 Japan Sympathomimetic Agents Market Size and Forecast (2017-2028)

8.3.4 South Korea Sympathomimetic Agents Market Size and Forecast (2017-2028)

8.3.5 India Sympathomimetic Agents Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Sympathomimetic Agents Market Size and Forecast (2017-2028)

8.3.7 Australia Sympathomimetic Agents Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Sympathomimetic Agents Revenue by Type (2017-2028)

9.2 South America Sympathomimetic Agents Revenue by Application (2017-2028)

9.3 South America Sympathomimetic Agents Market Size by Country

9.3.1 South America Sympathomimetic Agents Revenue by Country (2017-2028)

9.3.2 Brazil Sympathomimetic Agents Market Size and Forecast (2017-2028)

9.3.3 Argentina Sympathomimetic Agents Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Sympathomimetic Agents Revenue by Type (2017-2028)

10.2 Middle East & Africa Sympathomimetic Agents Revenue by Application (2017-2028)

10.3 Middle East & Africa Sympathomimetic Agents Market Size by Country

10.3.1 Middle East & Africa Sympathomimetic Agents Revenue by Country (2017-2028)

10.3.2 Turkey Sympathomimetic Agents Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Sympathomimetic Agents Market Size and Forecast (2017-2028)

10.3.4 UAE Sympathomimetic Agents Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Sympathomimetic Agents Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Sympathomimetic Agents Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Sympathomimetic Agents Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Sympathomimetic Agents Revenue (USD Million) by Region (2017-2022)

Table 5. Global Sympathomimetic Agents Revenue Market Share by Region (2023-2028)

Table 6. Pfizer Corporate Information, Head Office, and Major Competitors

Table 7. Pfizer Major Business

Table 8. Pfizer Sympathomimetic Agents Product and Solutions

Table 9. Pfizer Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Sanofi Corporate Information, Head Office, and Major Competitors

Table 11. Sanofi Major Business

Table 12. Sanofi Sympathomimetic Agents Product and Solutions

Table 13. Sanofi Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Novartis Corporate Information, Head Office, and Major Competitors

Table 15. Novartis Major Business

Table 16. Novartis Sympathomimetic Agents Product and Solutions

Table 17. Novartis Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Sterimax Corporate Information, Head Office, and Major Competitors

Table 19. Sterimax Major Business

Table 20. Sterimax Sympathomimetic Agents Product and Solutions

Table 21. Sterimax Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Bedford Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 23. Bedford Pharmaceuticals Major Business

Table 24. Bedford Pharmaceuticals Sympathomimetic Agents Product and Solutions

Table 25. Bedford Pharmaceuticals Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Teva Corporate Information, Head Office, and Major Competitors

Table 27. Teva Major Business

Table 28. Teva Sympathomimetic Agents Product and Solutions

Table 29. Teva Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Amneal Biosciences Corporate Information, Head Office, and Major Competitors

Table 31. Amneal Biosciences Major Business

Table 32. Amneal Biosciences Sympathomimetic Agents Product and Solutions

Table 33. Amneal Biosciences Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Baxter Laboratories Corporate Information, Head Office, and Major Competitors

Table 35. Baxter Laboratories Major Business

Table 36. Baxter Laboratories Sympathomimetic Agents Product and Solutions

Table 37. Baxter Laboratories Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Hikma Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 39. Hikma Pharmaceuticals Major Business

Table 40. Hikma Pharmaceuticals Sympathomimetic Agents Product and Solutions

Table 41. Hikma Pharmaceuticals Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Amphastar Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 43. Amphastar Pharmaceuticals Major Business

Table 44. Amphastar Pharmaceuticals Sympathomimetic Agents Product and Solutions

Table 45. Amphastar Pharmaceuticals Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Marathon Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 47. Marathon Pharmaceuticals Major Business

Table 48. Marathon Pharmaceuticals Sympathomimetic Agents Product and Solutions

Table 49. Marathon Pharmaceuticals Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Bausch Health Companies Corporate Information, Head Office, and Major Competitors

Table 51. Bausch Health Companies Major Business

Table 52. Bausch Health Companies Sympathomimetic Agents Product and Solutions

Table 53. Bausch Health Companies Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Sterling-Winthrop Corporate Information, Head Office, and Major Competitors

Table 55. Sterling-Winthrop Major Business

Table 56. Sterling-Winthrop Sympathomimetic Agents Product and Solutions

Table 57. Sterling-Winthrop Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Cipla USA Corporate Information, Head Office, and Major Competitors

Table 59. Cipla USA Major Business

Table 60. Cipla USA Sympathomimetic Agents Product and Solutions

Table 61. Cipla USA Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Nexus Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 63. Nexus Pharmaceuticals Major Business

Table 64. Nexus Pharmaceuticals Sympathomimetic Agents Product and Solutions

Table 65. Nexus Pharmaceuticals Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 66. Mylan Corporate Information, Head Office, and Major Competitors

Table 67. Mylan Major Business

Table 68. Mylan Sympathomimetic Agents Product and Solutions

Table 69. Mylan Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 70. Impax Corporate Information, Head Office, and Major Competitors

Table 71. Impax Major Business

Table 72. Impax Sympathomimetic Agents Product and Solutions

Table 73. Impax Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 74. ALK Abello Corporate Information, Head Office, and Major Competitors

Table 75. ALK Abello Major Business

Table 76. ALK Abello Sympathomimetic Agents Product and Solutions

Table 77. ALK Abello Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 78. Lincoln Medical Corporate Information, Head Office, and Major Competitors

Table 79. Lincoln Medical Major Business

Table 80. Lincoln Medical Sympathomimetic Agents Product and Solutions

Table 81. Lincoln Medical Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 82. Amphastar Corporate Information, Head Office, and Major Competitors

Table 83. Amphastar Major Business

Table 84. Amphastar Sympathomimetic Agents Product and Solutions

Table 85. Amphastar Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 86. Emerade Corporate Information, Head Office, and Major Competitors

Table 87. Emerade Major Business

Table 88. Emerade Sympathomimetic Agents Product and Solutions

Table 89. Emerade Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 90. Grand Pharma Corporate Information, Head Office, and Major Competitors

Table 91. Grand Pharma Major Business

Table 92. Grand Pharma Sympathomimetic Agents Product and Solutions

Table 93. Grand Pharma Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 94. Harvest Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 95. Harvest Pharmaceuticals Major Business

Table 96. Harvest Pharmaceuticals Sympathomimetic Agents Product and Solutions

Table 97. Harvest Pharmaceuticals Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 98. Merit Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 99. Merit Pharmaceutical Major Business

Table 100. Merit Pharmaceutical Sympathomimetic Agents Product and Solutions

Table 101. Merit Pharmaceutical Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 102. Tianjin Jinyao Group Corporate Information, Head Office, and Major Competitors

Table 103. Tianjin Jinyao Group Major Business

Table 104. Tianjin Jinyao Group Sympathomimetic Agents Product and Solutions

Table 105. Tianjin Jinyao Group Sympathomimetic Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 106. Global Sympathomimetic Agents Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 107. Global Sympathomimetic Agents Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 108. Breakdown of Sympathomimetic Agents by Company Type (Tier 1, Tier 2 and Tier 3)

Table 109. Sympathomimetic Agents Players Head Office, Products and Services Provided

Table 110. Sympathomimetic Agents Mergers & Acquisitions in the Past Five Years

Table 111. Sympathomimetic Agents New Entrants and Expansion Plans

Table 112. Global Sympathomimetic Agents Revenue (USD Million) by Type (2017-2022)

Table 113. Global Sympathomimetic Agents Revenue Share by Type (2017-2022)

Table 114. Global Sympathomimetic Agents Revenue Forecast by Type (2023-2028)

Table 115. Global Sympathomimetic Agents Revenue by Application (2017-2022)

Table 116. Global Sympathomimetic Agents Revenue Forecast by Application (2023-2028)

Table 117. North America Sympathomimetic Agents Revenue by Type (2017-2022) & (USD Million)

Table 118. North America Sympathomimetic Agents Revenue by Type (2023-2028) & (USD Million)

Table 119. North America Sympathomimetic Agents Revenue by Application (2017-2022) & (USD Million)

Table 120. North America Sympathomimetic Agents Revenue by Application (2023-2028) & (USD Million)

Table 121. North America Sympathomimetic Agents Revenue by Country (2017-2022) & (USD Million)

Table 122. North America Sympathomimetic Agents Revenue by Country (2023-2028) & (USD Million)

Table 123. Europe Sympathomimetic Agents Revenue by Type (2017-2022) & (USD Million)

Table 124. Europe Sympathomimetic Agents Revenue by Type (2023-2028) & (USD Million)

Table 125. Europe Sympathomimetic Agents Revenue by Application (2017-2022) & (USD Million)

Table 126. Europe Sympathomimetic Agents Revenue by Application (2023-2028) & (USD Million)

Table 127. Europe Sympathomimetic Agents Revenue by Country (2017-2022) & (USD Million)

Table 128. Europe Sympathomimetic Agents Revenue by Country (2023-2028) & (USD Million)

Table 129. Asia-Pacific Sympathomimetic Agents Revenue by Type (2017-2022) & (USD Million)

Table 130. Asia-Pacific Sympathomimetic Agents Revenue by Type (2023-2028) & (USD Million)

Table 131. Asia-Pacific Sympathomimetic Agents Revenue by Application (2017-2022) & (USD Million)

Table 132. Asia-Pacific Sympathomimetic Agents Revenue by Application (2023-2028) & (USD Million)

Table 133. Asia-Pacific Sympathomimetic Agents Revenue by Region (2017-2022) & (USD Million)

Table 134. Asia-Pacific Sympathomimetic Agents Revenue by Region (2023-2028) & (USD Million)

Table 135. South America Sympathomimetic Agents Revenue by Type (2017-2022) & (USD Million)

Table 136. South America Sympathomimetic Agents Revenue by Type (2023-2028) & (USD Million)

Table 137. South America Sympathomimetic Agents Revenue by Application (2017-2022) & (USD Million)

Table 138. South America Sympathomimetic Agents Revenue by Application (2023-2028) & (USD Million)

Table 139. South America Sympathomimetic Agents Revenue by Country (2017-2022) & (USD Million)

Table 140. South America Sympathomimetic Agents Revenue by Country (2023-2028) & (USD Million)

Table 141. Middle East & Africa Sympathomimetic Agents Revenue by Type (2017-2022) & (USD Million)

Table 142. Middle East & Africa Sympathomimetic Agents Revenue by Type (2023-2028) & (USD Million)

Table 143. Middle East & Africa Sympathomimetic Agents Revenue by Application (2017-2022) & (USD Million)

Table 144. Middle East & Africa Sympathomimetic Agents Revenue by Application (2023-2028) & (USD Million)

Table 145. Middle East & Africa Sympathomimetic Agents Revenue by Country (2017-2022) & (USD Million)

Table 146. Middle East & Africa Sympathomimetic Agents Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Sympathomimetic Agents Picture

Figure 2. Global Sympathomimetic Agents Revenue Market Share by Type in 2021

Figure 3. Dobutamine

Figure 4. Dopamine

Figure 5. Ephedrine

Figure 6. Epinephrine

Figure 7. Isoproterenol

Figure 8. Mephentermine

Figure 9. Metaraminol

Figure 10. Methoxamine

Figure 11. Norepinephrine

Figure 12. Phenylephrine

Figure 13. Sympathomimetic Agents Revenue Market Share by Application in 2021

Figure 14. Anaphylaxis Picture

Figure 15. Cardiac Arrest Picture

Figure 16. Others Picture

Figure 17. Global Sympathomimetic Agents Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 18. Global Sympathomimetic Agents Revenue and Forecast (2017-2028) & (USD Million)

Figure 19. Global Sympathomimetic Agents Revenue Market Share by Region (2017-2028)

Figure 20. Global Sympathomimetic Agents Revenue Market Share by Region in 2021

Figure 21. North America Sympathomimetic Agents Revenue (USD Million) and Growth Rate (2017-2028)

Figure 22. Europe Sympathomimetic Agents Revenue (USD Million) and Growth Rate (2017-2028)

Figure 23. Asia-Pacific Sympathomimetic Agents Revenue (USD Million) and Growth Rate (2017-2028)

Figure 24. South America Sympathomimetic Agents Revenue (USD Million) and Growth Rate (2017-2028)

Figure 25. Middle East and Africa Sympathomimetic Agents Revenue (USD Million) and Growth Rate (2017-2028)

Figure 26. Sympathomimetic Agents Market Drivers

Figure 27. Sympathomimetic Agents Market Restraints

Figure 28. Sympathomimetic Agents Market Trends

Figure 29. Pfizer Recent Developments and Future Plans

Figure 30. Sanofi Recent Developments and Future Plans

Figure 31. Novartis Recent Developments and Future Plans

Figure 32. Sterimax Recent Developments and Future Plans

Figure 33. Bedford Pharmaceuticals Recent Developments and Future Plans

Figure 34. Teva Recent Developments and Future Plans

Figure 35. Amneal Biosciences Recent Developments and Future Plans

Figure 36. Baxter Laboratories Recent Developments and Future Plans

Figure 37. Hikma Pharmaceuticals Recent Developments and Future Plans

Figure 38. Amphastar Pharmaceuticals Recent Developments and Future Plans

Figure 39. Marathon Pharmaceuticals Recent Developments and Future Plans

Figure 40. Bausch Health Companies Recent Developments and Future Plans

Figure 41. Sterling-Winthrop Recent Developments and Future Plans

Figure 42. Cipla USA Recent Developments and Future Plans

Figure 43. Nexus Pharmaceuticals Recent Developments and Future Plans

Figure 44. Mylan Recent Developments and Future Plans

Figure 45. Impax Recent Developments and Future Plans

Figure 46. ALK Abello Recent Developments and Future Plans

Figure 47. Lincoln Medical Recent Developments and Future Plans

Figure 48. Amphastar Recent Developments and Future Plans

Figure 49. Emerade Recent Developments and Future Plans

Figure 50. Grand Pharma Recent Developments and Future Plans

Figure 51. Harvest Pharmaceuticals Recent Developments and Future Plans

Figure 52. Merit Pharmaceutical Recent Developments and Future Plans

Figure 53. Tianjin Jinyao Group Recent Developments and Future Plans

Figure 54. Global Sympathomimetic Agents Revenue Share by Players in 2021

Figure 55. Sympathomimetic Agents Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 56. Global Top 3 Players Sympathomimetic Agents Revenue Market Share in 2021

Figure 57. Global Top 10 Players Sympathomimetic Agents Revenue Market Share in 2021

Figure 58. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 59. Global Sympathomimetic Agents Revenue Share by Type in 2021

Figure 60. Global Sympathomimetic Agents Market Share Forecast by Type (2023-2028)

Figure 61. Global Sympathomimetic Agents Revenue Share by Application in 2021

Figure 62. Global Sympathomimetic Agents Market Share Forecast by Application (2023-2028)

Figure 63. North America Sympathomimetic Agents Sales Market Share by Type (2017-2028)

Figure 64. North America Sympathomimetic Agents Sales Market Share by Application (2017-2028)

Figure 65. North America Sympathomimetic Agents Revenue Market Share by Country (2017-2028)

Figure 66. United States Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. Canada Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Mexico Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Europe Sympathomimetic Agents Sales Market Share by Type (2017-2028)

Figure 70. Europe Sympathomimetic Agents Sales Market Share by Application (2017-2028)

Figure 71. Europe Sympathomimetic Agents Revenue Market Share by Country (2017-2028)

Figure 72. Germany Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 73. France Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. United Kingdom Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Russia Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Italy Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. Asia-Pacific Sympathomimetic Agents Sales Market Share by Type (2017-2028)

Figure 78. Asia-Pacific Sympathomimetic Agents Sales Market Share by Application (2017-2028)

Figure 79. Asia-Pacific Sympathomimetic Agents Revenue Market Share by Region (2017-2028)

Figure 80. China Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. Japan Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 82. South Korea Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 83. India Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 84. Southeast Asia Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 85. Australia Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 86. South America Sympathomimetic Agents Sales Market Share by Type (2017-2028)

Figure 87. South America Sympathomimetic Agents Sales Market Share by Application (2017-2028)

Figure 88. South America Sympathomimetic Agents Revenue Market Share by Country (2017-2028)

Figure 89. Brazil Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 90. Argentina Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 91. Middle East and Africa Sympathomimetic Agents Sales Market Share by Type (2017-2028)

Figure 92. Middle East and Africa Sympathomimetic Agents Sales Market Share by Application (2017-2028)

Figure 93. Middle East and Africa Sympathomimetic Agents Revenue Market Share by Country (2017-2028)

Figure 94. Turkey Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 95. Saudi Arabia Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 96. UAE Sympathomimetic Agents Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 97. Methodology

Figure 98. Research Process and Data Source